Advertisement

New therapeutic signals in asthma

Blocking IL-5 or adding IL-12 can lower the number of eosinophils in mild asthma but has no effect on hyper-responsiveness.

By | January 5, 2001

The development of specific anti-inflammatory agents for the treatment of asthma is overdue, but new research provides scope for optimism. Two early reports suggest that therapeutic agents blocking signalling molecules interleukin-5 or supplementing interleukin-12 can lower the number of blood and sputum eosinophils in patients with mild asthma.

Professors Peter Barnes and Stephen Holgate from London and Southampton respectively, joined forces to study the effects of interleukin-5 blocking monoclonal antibody and recombinant human interleukin-12. In the two separate double-blind randomised placebo-controlled trials they found that a single dose of monoclonal antibody to interleukin-5 decreased blood eosinophils for up to 16 weeks and sputum eosinophils at 4 weeks (Lancet 2000; 356: 2144-48), and that intravenous administration of interleukin-12 caused a significant decrease in the blood and sputum eosinophil at 24 hours (Lancet 2000; 356: 2149-53).

However these are only the forward steps of the tango. The major backward step is the finding that the reduction of eosinophils had no significant effects on airway hyper-responsiveness or late asthmatic reaction. This questions the role of eosinophils in these reactions.

Advertisement

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Rainin Instrument
Rainin Instrument
Advertisement
Life Technologies